Taysha Gene Therapies Announces Participation in Upcoming Investor Healthcare Conferences

Rhea-AI Summary

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announces its participation in two upcoming virtual conferences: the Truist Fireside Chat on February 11, 2021, at 1:00 pm ET, and the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 8:40 am ET. Key participants include RA Session II, President and CEO, and Dr. Suyash Prasad, Chief Medical Officer. Audio webcasts will be accessible on Taysha's corporate website, with archived versions available for 60 days. Taysha focuses on developing gene therapies for central nervous system diseases, leveraging its integrated platform.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a virtual fireside chat for the Truist Fireside Chat series as well as the 10^th Annual SVB Leerink Global Healthcare Conference.

Conferences Details:

Event:		Truist Virtual Fireside Chat with Joon Lee, MD, PhD, Director and Senior Biotech Equity Research Analyst
Date:		Thursday, February 11, 2021
Time:		1:00 pm ET
Format:		Fireside chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer
		Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations
Event:		10th Annual SVB Leerink Global Healthcare Conference (Virtual)
Date:		Friday, February 26, 2021
Time:		8:40 am ET
Format:		Presentation
Participants:		RA Session II, President, Founder and CEO

Audio webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005323/en/

FAQ

What conferences will Taysha Gene Therapies participate in?

Taysha Gene Therapies will participate in the Truist Fireside Chat on February 11, 2021, and the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021.

What is the date and time for the Truist Fireside Chat?

The Truist Fireside Chat will take place on February 11, 2021, at 1:00 pm ET.

Who are the key participants in the Taysha Gene Therapies events?

Key participants include RA Session II, President and CEO, and Dr. Suyash Prasad, Chief Medical Officer.

When will the SVB Leerink Global Healthcare Conference be held?

The SVB Leerink Global Healthcare Conference will be held on February 26, 2021, at 8:40 am ET.

How can I access the audio webcasts for Taysha Gene Therapies events?

Audio webcasts for the events will be available in the 'Events & Media' section of Taysha's corporate website.